MAM
Oreo Choco Cr?me launches its new TVC
MUMBAI: Cadbury India, a part of Mondele-z International has announced the launch of a new TVC campaign for Oreo Choco Cr?me.
The ad campaign showcase the playful relationship shared by two brothers , the ad is developed by Interface Communications.
The ad is based on the insight that consumers love ‘Oreo’ for its chocolaty sandwich experience. It shows two young teenager boys enjoying Oreo Choco Cr?me and getting confused as to which is more chocolaty – the cream or the cookie. With real cocoa in both the cream and the cookie, that’s one debate that they find impossible to win, eventually switching sides multiple times.
Speaking on the campaign, Mondele-z International AVP marketing biscuits Chella Pandyan said, “It’s a well-established fact that chocolate is India’s favourite cream flavor. The uniqueness of Oreo Choco Cr?me is that both – the cookie and the cream are chocolaty. The TVC highlights the delightful dilemma the two brothers face of deciding which is more chocolaty!”
Interface Communications national creative director Robby Mathew added, “The campaign idea banks on the unique relationship that siblings share. What starts off as a coach-student relationship turns into one of equals, as they together discover Oreo Choco Cr?me’s double chocolaty delight.”
The main Tv campaign is supported by four short films that keep the debate and dilemma going.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
